DescriptionCurator's Comment: description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5176be07-3121-49fb-9eb9-638903753a31 | https://www.drugs.com/monograph/atracurium-besylate.html | http://www.wikidoc.org/index.php/Atracurium
Curator's Comment: description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5176be07-3121-49fb-9eb9-638903753a31 | https://www.drugs.com/monograph/atracurium-besylate.html | http://www.wikidoc.org/index.php/Atracurium
Atracurium is an intermediate-duration, nondepolarizing, skeletal muscle relaxant for intravenous administration. It is used, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Most adverse reactions were suggestive of histamine release. Common side effects include flushing of the skin and low blood pressure. Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2362997 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19417616 |
169.5 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | ATRACURIUM BESYLATE Approved UseAtracurium Besylate Injection, USP is indicated, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Launch Date1997 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010-12 |
|
| Marfan syndrome with acute abdomen: a case report. | 2010-11-10 |
|
| Wound contraction and macro-deformation during negative pressure therapy of sternotomy wounds. | 2010-09-30 |
|
| Cisatracurium in different doses versus atracurium during general anesthesia for abdominal surgery. | 2010-09 |
|
| Comparison between Culture Conditions Improving Growth and Differentiation of Blood and Bone Marrow Cells Committed to the Endothelial Cell Lineage. | 2010-02-06 |
|
| Modulation of temporal precision in thalamic population responses to natural visual stimuli. | 2010 |
|
| Anaesthetic management of post-burn contractures, a recurrent challenge from oil pipeline vandalization in Nigeria: a case report. | 2009-12-03 |
|
| Leaking abdominal aortic aneurysm on anticoagulants-thromboelastography assisted management. | 2009-06 |
|
| A prospective randomized double blind study to evaluate the effect of infusion of amino Acid enriched solution on recovery from neuromuscular blockade. | 2009-06 |
|
| Timing precision in population coding of natural scenes in the early visual system. | 2008-12-16 |
|
| Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. | 2007-06 |
|
| [Establishment of a hypothermic dog model to investigate airway rewarming]. | 2006-08 |
|
| Dynamic encoding of natural luminance sequences by LGN bursts. | 2006-07 |
|
| A comparison of the efficacy of cisatracurium and atracurium in kidney transplantation operation. | 2004-01 |
|
| [Interaction of donepezil and muscular blockers in Alzheimer's disease]. | 2003-02 |
|
| [Relaxation and the electromyographic identification of the recurrent laryngeal nerve]. | 2002-09 |
|
| Synthesis and structure-activity relationships of neuromuscular blocking agents. | 2002-08 |
Patents
Sample Use Guides
An atracurium besylate dose of 0.4 to 0.5 mg/kg (1.7 to 2.2 times the ED95), given as an intravenous bolus injection, is the recommended initial dose for most patients. Maximum neuromuscular block achieved approximately 3 to 5 minutes after injection.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2720863
Exposure of isolated rat hepatocytes to atracurium produced cellular damage evidenced by extrusion of an intracellular enzyme, lactate dehydrogenase (LDH), into the incubation medium. Leakage of LDH was directly related to the concentration of atracurium in the medium (250 to 800 microM). When atracurium was added to the medium and the medium immediately added to hepatocytes, the leakage of LDH increased as the concentration of atracurium increased (P < 0.001 for the comparison with cells not exposed to atracurium).
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29696
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
4734
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
PRIMARY | |||
|
SUB05603MIG
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
PRIMARY | |||
|
264-743-4
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
PRIMARY | |||
|
DB00732
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
PRIMARY | |||
|
1219
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
PRIMARY | RxNorm | ||
|
C28839
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
PRIMARY | |||
|
CHEMBL1360
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
PRIMARY | |||
|
760047
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
PRIMARY | |||
|
DTXSID6022630
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
PRIMARY | |||
|
64228-81-5
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
PRIMARY | |||
|
m2129
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
PRIMARY | Merck Index | ||
|
40AX66P76P
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
PRIMARY | |||
|
ATRACURIUM BESILATE
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
PRIMARY | |||
|
1044800
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
PRIMARY | |||
|
2915
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
PRIMARY | |||
|
100000085206
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
PRIMARY | |||
|
T-90
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
PRIMARY | |||
|
40AX66P76P
Created by
admin on Mon Mar 31 18:20:00 GMT 2025 , Edited by admin on Mon Mar 31 18:20:00 GMT 2025
|
PRIMARY |
All of the following components must be present:
ACTIVE MOIETY
SUBSTANCE RECORD